^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAR20.19.22 T

    i
    Other names: CAR20.19.22 T
    Associations

    News

    Trials
    Company:
    Medical College of Wisconsin, Miltenyi Biotec
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3ms
    CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=4, Terminated, Medical College of Wisconsin | All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR20.19.22 T
    over1year
    CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR20.19.22 T
    almost2years
    CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=48, Recruiting, Medical College of Wisconsin | N=36 --> 48
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR20.19.22 T
    over2years
    CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=36, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR20.19.22 T